
Arvinas fell 38.8% from $11.02 to $6.74, behind the S&P 500's +9.7%. Its worst day was Nov 5 (−11.7%), and its low came Nov 6 at $6.41.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Arvinas closed at its highest level of the year, 25.5% above where the year started.
+3.4% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
Arvinas shares fell 9.6%, while the S&P 500 fell 1.5%.
−9.6% · S&P 500 −1.5%
EPS of $-1.10 missed the $-0.56 estimate on $9.5M revenue (est. $35.6M).
+0.6% · S&P 500 +0.7%
ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy.ARV-102 was well tolerated across all dose levels following 28 days of once-dailyARV-10…
−9.3% · S&P 500 −1.4%
EPS of $-0.90 beat the $-0.96 estimate on $15.6M revenue (est. $16.4M).
−0.9% · S&P 500 −0.2%
EPS of $2.58 beat the $-0.26 estimate on $249.7M revenue (est. $56.6M).
+11.7%, the year's best day, on 3M shares, the year's heaviest volume · S&P 500 +1.8%
Arvinas shares fell 8.0%, while the S&P 500 fell 0.7%.
−8.0% · S&P 500 −0.7%
Arvinas shares fell 8.2%, while the S&P 500 fell 0.0%.
−8.2% · S&P 500 0.0%
EPS of $-0.82 beat the $-0.92 estimate on $500,000.00 revenue (est. $18.7M).
−5.7% · S&P 500 +0.3%
Where it ended: a close of $6.74 on Nov 19, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $-0.75, revenue est. $13.1M).
Nothing in the past 12 months.
All ARVN dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ARVN and SPY from Benzinga historical bars. Not investment advice.